Updated:
Novanta
Novanta began in 1968 as GSI Group, a laser-systems spinoff from The MITRE Corporation, and later rebranded in 2016 to signal its focus on precision...
Novanta
Novanta began in 1968 as GSI Group, a laser-systems spinoff from The MITRE Corporation, and later rebranded in 2016 to signal its focus on precision medicine and advanced-industrial subsystems. The firm's CEO since 2017, Matthijs Glastra, previously led the medical-technologies unit as president and has structured acquisitions around three core platforms: Celera Motion for servo drives and motors, ATI Industrial Automation for robotic end-effectors, and Laser Quantum for solid-state and ultrafast lasers. Public records show Novanta serves instrument, diagnostic, and surgical-robotics OEMs, with its components embedded in systems from Intuitive Surgical and Carl Zeiss Meditec, alongside semiconductor-capital-equipment and laser-additive-manufacturing customers. Novanta deploys capital through an acquisition-led growth strategy, targeting founder-owned precision-component businesses with $15 million to $100 million in revenue that design into regulated medical and industrial workflows. Since 2016, the firm has closed over a dozen acquisitions, including the 2023 purchase of Motion Solutions to deepen custom-engineered motion subsystems, and the 2019 acquisition of Ingenia Motion Control to expand direct-drive servo capabilities. Its operating model centralizes supply-chain management, regulatory compliance, and Asia-Pacific distribution while preserving brand autonomy and engineering talent at each acquired entity. The portfolio spans three continents, with major engineering hubs in Bedford, Massachusetts; Garching, Germany; and Weymouth, United Kingdom. As of early 2025, Novanta employs more than 2,700 people and reports roughly $900 million in trailing revenue, with roughly 60% tied to medical-device OEMs and the balance to advanced-industrial end markets. The firm maintains 11 design and manufacturing centers across North America, Europe, and Asia, reflecting an integrated global supply chain that supports the sterile-packaging, laser-marking, and robotic-automation segments. In December 2023, Novanta acquired Motion Solutions, a California-based custom-engineered motion subsystem provider, to strengthen its position in semiconductor and life-sciences capital equipment. The firm reports quarterly financials under NASDAQ ticker NOVT and operates without a separate family-office or limited-partnership vehicle — its public-equity float serves as the permanent-capital base for the acquisition strategy. Unlike private equity sponsors or single-family offices, Novanta holds businesses indefinitely, facilitating multi-decade technology roadmaps that align with medical-device regulatory cycles and industrial-automation capex trends. This permanent-ownership architecture allows operating-company founders to exit while preserving their engineering culture and customer franchises inside a publicly traded entity that can fund further acquisitions through its balance sheet. The structure functions as a hybrid between a strategic consolidator and a long-duration industrial holding company, a profile uncommon among precision-technology acquirers.
General information
Firm type
Other
Year founded
1968
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Bedford
Corporate office
Bedford, MA, United States
Principals
Matthijs Glastra
Chief Executive Officer
Sector focus
Frequently asked questions
How does Novanta source and evaluate acquisition targets?
Novanta focuses on founder-owned precision-component manufacturers with $15 million to $100 million in revenue that already hold regulatory approvals and design positions inside medical-device or advanced-industrial workflows. The firm's business-development team and CEO evaluate targets against a disciplined financial screen and a technology-fit assessment tied to existing photonics, motion, and vision platforms. Integration is structured to preserve the target's brand identity and engineering bench while layering on Novanta's global distribution and centralized supply-chain functions.
Is Novanta a holding company, a private equity firm, or an operating business?
Novanta is a publicly traded corporation (Nasdaq: NOVT) that functions as a long-duration industrial holding company for precision-technology businesses. Unlike private equity funds, it uses its public equity as permanent capital and does not operate under finite fund lives or limited-partner structures. It retains acquired companies indefinitely and reports consolidated financials, with CEO Matthijs Glastra overseeing both organic engineering milestones and the acquisition pipeline.
What types of original-equipment manufacturers buy Novanta's components?
Novanta's subsystems are embedded in products from surgical-robotics companies including Intuitive Surgical, diagnostic instrument makers such as Carl Zeiss Meditec, and semiconductor-capital-equipment manufacturers. The firm's Celera Motion servo drives, ATI robotic end-effectors, and Laser Quantum lasers serve instrument OEMs, sterile-packaging lines, and additive-manufacturing systems, with roughly 60% of revenue tied to healthcare applications.
Does Novanta take controlling stakes or minority positions?
Novanta exclusively acquires controlling stakes, fully integrating target businesses into its operating structure. The firm does not make minority investments or participate in external venture funds. Each acquisition is structured as a full purchase, with the acquired company becoming a division or subsidiary within one of the three platform brands.
How is Novanta different from a roll-up consolidator or serial acquirer?
Unlike a traditional roll-up, Novanta maintains separate brand identities and engineering autonomy at each acquired business while centralizing back-office, supply-chain, and regulatory functions. The firm targets niche component suppliers with proprietary technology rather than fragmented service businesses, and it holds them permanently under a public-company governance framework, creating a structural profile closer to a diversified industrial than a serial consolidator.
Who runs capital allocation and acquisition strategy at Novanta?
CEO Matthijs Glastra leads capital allocation alongside the CFO and business-unit presidents. Glastra joined Novanta in 2012, became president of the medical technologies segment, and was appointed CEO in 2017, and has since overseen more than a dozen acquisitions. The board reviews significant transactions, but deal origination, valuation, and integration planning are centralized under the Bedford, Massachusetts, leadership team.
Does Novanta operate philanthropic or family-office structures alongside its business?
Novanta does not operate a family-office, foundation, or donor-advised fund structure — it is exclusively a publicly traded industrial-technology corporation. The firm's corporate responsibility reporting and ESG disclosures are published within its SEC filings and annual sustainability summaries, with no separate philanthropic vehicle disclosed in public records.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: